These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 24696615)
1. Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer. Deng W; Wang QW; Zhang XT; Lu M; Li J; Li Y; Gong JF; Zhou J; Lu ZH; Shen L World J Gastroenterol; 2014 Mar; 20(12):3356-63. PubMed ID: 24696615 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India. Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey. Teker F; Yilmaz B; Kemal Y; Kut E; Yucel I Asian Pac J Cancer Prev; 2014; 15(16):6727-32. PubMed ID: 25169516 [TBL] [Abstract][Full Text] [Related]
4. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution. Inal A; Kaplan MA; Kucukoner M; Isikdogan A Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. He MM; Zhang DS; Wang F; Wang ZQ; Luo HY; Ren C; Jin Y; Chen DL; Xu RH World J Gastroenterol; 2014 Jan; 20(1):264-73. PubMed ID: 24415881 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). De Vita F; Giuliani F; Orditura M; Maiello E; Galizia G; Di Martino N; Montemurro F; Cartenì G; Manzione L; Romito S; Gebbia V; Ciardiello F; Catalano G; Colucci G; Ann Oncol; 2007 Aug; 18(8):1354-8. PubMed ID: 17525087 [TBL] [Abstract][Full Text] [Related]
7. [Impact of AJCC staging system (2010 edition) on the choice of postoperative adjuvant chemotherapy after radical resection of gastric cancer]. Yu YY; Liu TS; Wang ZM; Li W Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Jun; 15(6):599-602. PubMed ID: 22736131 [TBL] [Abstract][Full Text] [Related]
8. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. Fazio N; Biffi R; Maibach R; Hayoz S; Thierstein S; Brauchli P; Bernhard J; Stupp R; Andreoni B; Renne G; Crosta C; Morant R; Chiappa A; Luca F; Zampino MG; Huber O; Goldhirsch A; de Braud F; Roth AD; ; Ann Oncol; 2016 Apr; 27(4):668-73. PubMed ID: 26712905 [TBL] [Abstract][Full Text] [Related]
9. Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. Di Bartolomeo M; Buzzoni R; Mariani L; Ferrario E; Katia D; Gevorgyan A; Zilembo N; Bordonaro R; Bochicchio AM; Massidda B; Ardizzoia A; Marini G; Aitini E; Schieppati G; Comella G; Pinotti G; Palazzo S; Cicero G; Bajetta E; ; Villa E; Fagnani D; Reguzzoni G; Agostana B; Oliani C; Kildani B; Duro M; Botta M; Mozzana R; Mantovani G Oncology; 2006; 71(5-6):341-6. PubMed ID: 17855795 [TBL] [Abstract][Full Text] [Related]
11. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer. Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction. Ryoo BY; Kang YK; Im YH; Kim YJ; Kim BS; Kim TY; Jung SH; Park JH; Baek HJ; Kim YC; Shim YM; Kim CM; Zo JI Am J Clin Oncol; 1999 Jun; 22(3):253-7. PubMed ID: 10362331 [TBL] [Abstract][Full Text] [Related]
13. The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer. Guo MG; Zheng Q; Cheng Z; Wang Y; Feng CN; Yang Z Surg Oncol; 2010 Mar; 19(1):1-3. PubMed ID: 19006661 [TBL] [Abstract][Full Text] [Related]
14. Impact of adjuvant chemotherapy cycles on prognosis of resectable stomach cancer: a retrospective analysis. Zhang WY; Zhang WJ; Bai Y; Yuan HH; Liu F; Gao J; Gong YF; Jiang B Asian Pac J Cancer Prev; 2013; 14(1):381-6. PubMed ID: 23534757 [TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer : a propensity-matched analysis. Quan R; Huang J; Chen H; Liao Y; Lv W; Chen N; Liu J; Zhang H; Xu D Oncotarget; 2016 Nov; 7(46):76316-76326. PubMed ID: 27602756 [TBL] [Abstract][Full Text] [Related]
16. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Bajetta E; Floriani I; Di Bartolomeo M; Labianca R; Falcone A; Di Costanzo F; Comella G; Amadori D; Pinto C; Carlomagno C; Nitti D; Daniele B; Mini E; Poli D; Santoro A; Mosconi S; Casaretti R; Boni C; Pinotti G; Bidoli P; Landi L; Rosati G; Ravaioli A; Cantore M; Di Fabio F; Aitini E; Marchet A; Ann Oncol; 2014 Jul; 25(7):1373-1378. PubMed ID: 24728035 [TBL] [Abstract][Full Text] [Related]
17. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843 [TBL] [Abstract][Full Text] [Related]
18. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Lee CK; Jung M; Kim HS; Jung I; Shin DB; Kang SY; Zang DY; Kim KH; Lee MH; Kim BS; Lee KH; Cheong JH; Hyung WJ; Noh SH; Chung HC; Rha SY Cancer Res Treat; 2019 Jan; 51(1):1-11. PubMed ID: 29397659 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study. Chen L; Zhang C; Yao Z; Cui M; Xing J; Yang H; Zhang N; Liu M; Xu K; Tan F; Li Y; Jiang B; Su X BMC Cancer; 2021 Aug; 21(1):974. PubMed ID: 34461860 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant Concurrent Chemoradiotherapy (CRT) plus Docetaxel-Cisplatin-Fluorouracil (DCF) versus CRT plus Fluorouracil-Folinic Acid (FUFA) in Stage III Gastric Cancer. Alkan A; Mızrak D; Yaşar A; Karcı E; Köksoy EB; Ürün M; Özyurt N; Kuştaş AA; Kütük T; Ürün Y; Şenler FÇ; Akyürek S; Utkan G; Demirkazık A; Gökçe ŞÇ; Akbulut H J Cancer Res Ther; 2024 Apr; 20(3):913-917. PubMed ID: 39023597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]